BIGT Stock Price | L&G Pharma Breakthrough UCITS ETF P/E, Revenue, EPS, & Forecasts

L&G Pharma Breakthrough UCITS ETF • BIGT

BIGT current price

GBX 7.92-2.33%

Capital at risk.

About
Metrics
Sector breakdown
Regional breakdown
Top 10 Holdings
FAQs
News

-2.94%

-2.70%

-0.25%

+2.05%

-2.33%

MAX

+10.10%

About L&G Pharma Breakthrough UCITS ETF

Base currency

$ USD

Trading Cyrrency

GBX

ISIN

IE00BF0H7608

Trading on

LSE

Ticker

BIGT

Fund manager

LGIM Managers (Europe) Limited

Key facts & metrics

BasicAdvanced

Fund size

£18.1M

income

Distributing

Expense Ratio

49.00%

Dividend Yield

0.95208

Valuation

Price to prospective earnings

14.42

Price to book

3.14

Price to sales

2.35

Price to cashflow

10.84

Price

52-week High

GBX 865.20

52-week Low

GBX 721.90

50-day moving average

GBX 830.63

200-day moving average

GBX 796.21

Technicals

YTD

2.63%

Year 1

2.11%

Year 3

5.18%

Year 5

0.01%

Year 10

0.00%

Volatility Year 1

14.00%

Volatility Year 3

14.72%

Expected Return Year 3

3.73%

Sharpe Ratio

0.50%

Growth

Long term projected earnings

12.85%

Historical earnings

8.45%

Sales

5.62%

Cash flow

9.38%

Book value

6.32%

Sector breakdown

Healthcare

% 97,87

Materials

% 2,13

Regional breakdown

North America

% 56,03

Asia

% 22,66

Europe

% 16,63

Australia

% 2,42

% 2,26

Top 10 Holdings

Pharma Mar SAU

5.32%

Xeris Pharmaceuticals Inc

3.91%

Innocare Pharma Ltd

3.38%

Bristol-Myers Squibb

3.33%

Argen-X

3.33%

Jazz Pharmaceuticals

3.3%

Ligand Pharmaceuticals Incorporated

3.24%

Catalyst Pharmaceuticals Inc

3.15%

Nippon Shinyaku

3.08%

Supernus Pharmaceuticals Inc

3.04%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

What is the name of BIGT?

The name of BIGT is L&G Pharma Breakthrough UCITS ETF.

What is the ticker of L&G Pharma Breakthrough UCITS ETF?

The primary ticker of L&G Pharma Breakthrough UCITS ETF is BIGT.

What is the ISIN of L&G Pharma Breakthrough UCITS ETF?

The ISIN of L&G Pharma Breakthrough UCITS ETF is IE00BF0H7608.

What are the costs of L&G Pharma Breakthrough UCITS ETF

The total expense ratio (TER) of L&G Pharma Breakthrough UCITS ETF amounts to 49.00% p.a. These costs are withdrawn continuously from the fund assets and already included in the performance of the ETF. You don't have to pay them separately.

Does L&G Pharma Breakthrough UCITS ETF pay dividends?

Yes, L&G Pharma Breakthrough UCITS ETF does pay dividends.

What currency is L&G Pharma Breakthrough UCITS ETF traded in?

L&G Pharma Breakthrough UCITS ETF is traded in GBX.

Is L&G Pharma Breakthrough UCITS ETF an accumulating or distributing ETF?

L&G Pharma Breakthrough UCITS ETF is distributing.

Who is the fund manager of “L&G Pharma Breakthrough UCITS ETF?

The fund manager of L&G Pharma Breakthrough UCITS ETF is LGIM Managers (Europe) Limited.

What is the fund size of L&G Pharma Breakthrough UCITS ETF?

The fund size of L&G Pharma Breakthrough UCITS ETF is £18.1M.

L&G Pharma Breakthrough UCITS ETF news

thumbs_up_down

•Neutral

PCE Data Lower Than Expected, NVO Falls on New Obesity Drug, AFRM Upgraded

Jenny Horne joins the Futures show with live reaction to the latest PCE inflation data. November rate rose just 0.1% from October, but on an annual basis checked in at 2.4% On the stock front, Novo Nordisk (NVO) slid sharply after disappointing clinical data for its new obesity drug CagriSema.

Schwab Network•13h ago

thumb_up_alt

•Positive

Novo Nordisk Stock: A Rare Buying Opportunity

As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a rare buying opportunity to buy NVO stock at about fair stock price, judging by the long-term average valuation ratios. The business experienced 22.7% YoY revenue growth in US dollars during Q3 FY2024 and managed to expand its EBIT margin to over 47% (+95 bps QoQ and +161 bps YoY).

Seeking Alpha•13h ago

thumb_down_alt

•Negative

Novo Nordisk shares drop after weight loss drug trial disappoints

Novo Nordisk (NYSE:NVO) shares plunged more than 20% before Friday's opening bell after the drugmaker reported results from a late-stage trial of its weight loss drug CagriSema that fell short of expectations. The company reported that patients in the trial achieved weight loss of 22.7% after 68 weeks, below the 25% it had previously guided.

Proactive Investors•13h ago